Protein aggregation and neurodegenerative diseases: From theory to therapy

European Journal of Medicinal Chemistry

Volumn 124, Issue , 2016, Pages 1105-1120

  Kumar, Vijay ^a   Sami, Neha ^a   Kashav, Tara ^b   Islam, Asimul ^a   Ahmad, Faizan ^a   Hassan, Md Imtaiyaz ^a  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

^b CENTRAL UNIVERSITY OF SOUTH BIHAR   (India)

Author keywords

Cell toxicity; Drug target; Misfolding and aggregation; Neurodegenerative diseases; Therapeutic intervention

Indexed keywords

PROTEIN AGGREGATE;

ARTICLE; CYTOTOXICITY; DEGENERATIVE DISEASE; HUMAN; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN MISFOLDING; ANIMAL; CELL DEATH; CLINICAL TRIAL (TOPIC); COMPLICATION; METABOLISM; NERVE CELL; NEURODEGENERATIVE DISEASES; PATHOLOGY; PROTEOSTASIS DEFICIENCY;

ANIMALS; CELL DEATH; CLINICAL TRIALS AS TOPIC; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS; PROTEIN AGGREGATES; PROTEOSTASIS DEFICIENCIES;

EID: 84995581912     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.07.054     Document Type: Article

References (279)

1. [1] Ellis, R.J., Minton, A.P., Protein aggregation in crowded environments. Biol. Chem. 387 (2006), 485–497.
2. [2] van den Berg, B., Wain, R., Dobson, C.M., Ellis, R.J., Macromolecular crowding perturbs protein refolding kinetics: implications for folding inside the cell. EMBO J. 19 (2000), 3870–3875.
3. [3] Hartl, F.U., Molecular chaperones in cellular protein folding. Nature 381 (1996), 571–579.
4. [4] Hartl, F.U., Hayer-Hartl, M., Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295 (2002), 1852–1858.
5. [5] Lindquist, S.L., Kelly, J.W., Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb. Perspect. Biol., 3, 2011.
6. [6] Kim, Y.E., Hipp, M.S., Bracher, A., Hayer-Hartl, M., Hartl, F.U., Molecular chaperone functions in protein folding and proteostasis. Annu. Rev. Biochem. 82 (2013), 323–355.
7. [7] Balch, W.E., Morimoto, R.I., Dillin, A., Kelly, J.W., Adapting proteostasis for disease intervention. Science 319 (2008), 916–919.
8. [8] Herczenik, E., Gebbink, M.F., Molecular and cellular aspects of protein misfolding and disease. FASEB J. 22 (2008), 2115–2133.
9. [9] Chiti, F., Dobson, C.M., Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75 (2006), 333–366.
10. [10] van Ham, T.J., Breitling, R., Swertz, M.A., Nollen, E.A., Neurodegenerative diseases: lessons from genome-wide screens in small model organisms. EMBO Mol. Med. 1 (2009), 360–370.
11. [11] Soto, C., Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4 (2003), 49–60.
12. [12] Ross, C.A., Poirier, M.A., Protein aggregation and neurodegenerative disease. Nat. Med. 10:Suppl. (2004), S10–S17.
13. [13] Skovronsky, D.M., Lee, V.M., Trojanowski, J.Q., Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol. 1 (2006), 151–170.
14. [14] Forman, M.S., Trojanowski, J.Q., Lee, V.M., Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 10 (2004), 1055–1063.
15. [15] Haque, M.A., Ubaid-Ullah, S., Zaidi, S., Hassan, M.I., Islam, A., Batra, J.K., Ahmad, F., Characterization of pre-molten globule state of yeast iso-1-cytochrome c and its deletants at pH 6.0 and 25 degrees C. Int. J. Biol. Macromol. 72 (2015), 1406–1418.
16. [16] Haque, M.A., Zaidi, S., Ubaid-Ullah, S., Prakash, A., Hassan, M.I., Islam, A., Batra, J.K., Ahmad, F., In vitro and in silico studies of urea-induced denaturation of yeast iso-1-cytochrome c and its deletants at pH 6.0 and 25 degrees C. J. Biomol. Struct. Dyn. 33 (2014), 1493–1502.
17. [17] Zaidi, S., Haque, M.A., Ubaid-Ullah, S., Prakash, A., Hassan, M.I., Islam, A., Batra, J.K., Ahmad, F., Denatured states of yeast cytochrome c induced by heat and guanidinium chloride are structurally and thermodynamically different. J. Biomol. Struct. Dyn., 2016, 1–16.
18. [18] Zaidi, S., Hassan, M.I., Islam, A., Ahmad, F., The role of key residues in structure, function, and stability of cytochrome-c. Cell Mol. Life Sci. 71 (2014), 229–255.
19. [19] Glenner, G.G., Wong, C.W., Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120 (1984), 885–890.
20. [20] Lee, V.M., Balin, B.J., Otvos, L. Jr., Trojanowski, J.Q., A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251 (1991), 675–678.
21. [21] Dev, K.K., Hofele, K., Barbieri, S., Buchman, V.L., van der Putten, H., Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45 (2003), 14–44.
22. [22] Prusiner, S.B., Shattuck lecture–neurodegenerative diseases and prions. N. Engl. J. Med. 344 (2001), 1516–1526.
23. [23] Zoghbi, H.Y., Orr, H.T., Polyglutamine diseases: protein cleavage and aggregation. Curr. Opin. Neurobiol. 9 (1999), 566–570.
24. [24] Valentine, J.S., Doucette, P.A., Zittin Potter, S., Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu. Rev. Biochem. 74 (2005), 563–593.
25. [25] Kumar, V., Islam, A., Hassan, M.I., Ahmad, F., Delineating the relationship between amyotrophic lateral sclerosis and frontotemporal dementia: sequence and structure-based predictions. Biochim. Biophys. Acta, 1862, 1742–1754.
26. [26] Uversky, V.N., The triple power of D(3): protein intrinsic disorder in degenerative diseases. Front. Biosci. (Landmark Ed). 19 (2014), 181–258.
27. [27] Dunker, A.K., Silman, I., Uversky, V.N., Sussman, J.L., Function and structure of inherently disordered proteins. Curr. Opin. Struct. Biol. 18 (2008), 756–764.
28. [28] Uversky, V.N., Amyloidogenesis of natively unfolded proteins. Curr. Alzheimer Res. 5 (2008), 260–287.
29. [29] Uversky, V.N., Oldfield, C.J., Dunker, A.K., Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu. Rev. Biophys. 37 (2008), 215–246.
30. [30] Vacic, V., Iakoucheva, L.M., Disease mutations in disordered regions–exception to the rule?. Mol. Biosyst. 8 (2012), 27–32.
31. [31] Ward, J.J., Sodhi, J.S., McGuffin, L.J., Buxton, B.F., Jones, D.T., Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J. Mol. Biol. 337 (2004), 635–645.
32. [32] Hoang, T.X., Marsella, L., Trovato, A., Seno, F., Banavar, J.R., Maritan, A., Common attributes of native-state structures of proteins, disordered proteins, and amyloid. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 6883–6888.
33. [33] Khan, P., Parkash, A., Islam, A., Ahmad, F., Hassan, M.I., Molecular basis of the structural stability of hemochromatosis factor E: a combined molecular dynamic simulation and GdmCl-induced denaturation study. Biopolymers 105 (2016), 133–142.
34. [34] Naz, H., Shahbaaz, M., Bisetty, K., Islam, A., Ahmad, F., Hassan, M.I., Effect of pH on the structure, function, and stability of human calcium/calmodulin-dependent protein kinase IV: combined spectroscopic and MD simulation studies. Biochem. Cell Biol. 94 (2016), 221–228.
35. [35] Naz, H., Shahbaaz, M., Haque, M.A., Bisetty, K., Islam, A., Ahmad, F., Hassan, M.I., Urea-induced denaturation of human calcium/calmodulin-dependent protein kinase IV: a combined spectroscopic and MD simulation studies. J. Biomol. Struct. Dyn., 2016, 1–13.
36. [36] Rahaman, H., Alam Khan, M.K., Hassan, M.I., Islam, A., Moosavi-Movahedi, A.A., Ahmad, F., Heterogeneity of equilibrium molten globule state of cytochrome c induced by weak salt denaturants under physiological condition. PLoS One, 10, 2015, e0120465.
37. [37] Hassan, I., Ahmad, F., Structural diversity of class I MHC-like molecules and its implications in binding specificities. Adv. Protein Chem. Struct. Biol. 83 (2011), 223–270.
38. [38] Naiyer, A., Hassan, M.I., Islam, A., Sundd, M., Ahmad, F., Structural characterization of MG and pre-MG states of proteins by MD simulations, NMR, and other techniques. J. Biomol. Struct. Dyn. 33 (2015), 2267–2284.
39. [39] Bartlett, A.I., Radford, S.E., An expanding arsenal of experimental methods yields an explosion of insights into protein folding mechanisms. Nat. Struct. Mol. Biol. 16 (2009), 582–588.
40. [40] Dobson, C.M., Ellis, R.J., Protein folding and misfolding inside and outside the cell. EMBO J. 17 (1998), 5251–5254.
41. [41] Jahn, T.R., Radford, S.E., Folding versus aggregation: polypeptide conformations on competing pathways. Arch. Biochem. Biophys. 469 (2008), 100–117.
42. [42] Dinner, A.R., Sali, A., Smith, L.J., Dobson, C.M., Karplus, M., Understanding protein folding via free-energy surfaces from theory and experiment. Trends Biochem. Sci. 25 (2000), 331–339.
43. [43] Jahn, T.R., Radford, S.E., The Yin and Yang of protein folding. FEBS J. 272 (2005), 5962–5970.
44. [44] Soto, C., Protein misfolding and disease; protein refolding and therapy. FEBS Lett. 498 (2001), 204–207.
45. [45] Kelly, J.W., Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol. 6 (1996), 11–17.
46. [46] Konno, T., Amyloid-induced aggregation and precipitation of soluble proteins: an electrostatic contribution of the Alzheimer's beta(25-35) amyloid fibril. Biochemistry 40 (2001), 2148–2154.
47. [47] Ciani, B., Hutchinson, E.G., Sessions, R.B., Woolfson, D.N., A designed system for assessing how sequence affects alpha to beta conformational transitions in proteins. J. Biol. Chem. 277 (2002), 10150–10155.
48. [48] Chiti, F., Stefani, M., Taddei, N., Ramponi, G., Dobson, C.M., Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424 (2003), 805–808.
49. [49] Tjernberg, L., Hosia, W., Bark, N., Thyberg, J., Johansson, J., Charge attraction and beta propensity are necessary for amyloid fibril formation from tetrapeptides. J. Biol. Chem. 277 (2002), 43243–43246.
50. [50] Tartaglia, G.G., Pawar, A.P., Campioni, S., Dobson, C.M., Chiti, F., Vendruscolo, M., Prediction of aggregation-prone regions in structured proteins. J. Mol. Biol. 380 (2008), 425–436.
51. [51] Santiveri, C.M., Santoro, J., Rico, M., Jimenez, M.A., Factors involved in the stability of isolated beta-sheets: turn sequence, beta-sheet twisting, and hydrophobic surface burial. Protein Sci. 13 (2004), 1134–1147.
52. [52] Lee, J., Dubey, V.K., Longo, L.M., Blaber, M., A logical OR redundancy within the Asx-Pro-Asx-Gly type I beta-turn motif. J. Mol. Biol. 377 (2008), 1251–1264.
53. [53] Marcelino, A.M., Gierasch, L.M., Roles of beta-turns in protein folding: from peptide models to protein engineering. Biopolymers 89 (2008), 380–391.
54. [54] Tartaglia, G.G., Vendruscolo, M., Proteome-level interplay between folding and aggregation propensities of proteins. J. Mol. Biol. 402 (2010), 919–928.
55. [55] Cohen, S.I., Vendruscolo, M., Dobson, C.M., Knowles, T.P., From macroscopic measurements to microscopic mechanisms of protein aggregation. J. Mol. Biol. 421 (2012), 160–171.
56. [56] Kelly, J.W., The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 8 (1998), 101–106.
57. [57] Bemporad, F., Chiti, F., Protein misfolded oligomers: experimental approaches, mechanism of formation, and structure-toxicity relationships. Chem. Biol. 19 (2012), 315–327.
58. [58] Lashuel, H.A., Petre, B.M., Wall, J., Simon, M., Nowak, R.J., Walz, T., Lansbury, P.T. Jr., Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322 (2002), 1089–1102.
59. [59] Poirier, M.A., Li, H., Macosko, J., Cai, S., Amzel, M., Ross, C.A., Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 277 (2002), 41032–41037.
60. [60] Moreno-Gonzalez, I., Soto, C., Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Semin. Cell Dev. Biol. 22 (2011), 482–487.
61. [61] Stefani, M., Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits. Prog. Neurobiol. 99 (2012), 226–245.
62. [62] Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C.M., Stefani, M., Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416 (2002), 507–511.
63. [63] Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., Glabe, C.G., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003), 486–489.
64. [64] Malmo, C., Vilasi, S., Iannuzzi, C., Tacchi, S., Cametti, C., Irace, G., Sirangelo, I., Tetracycline inhibits W7FW14F apomyoglobin fibril extension and keeps the amyloid protein in a pre-fibrillar, highly cytotoxic state. FASEB J. 20 (2006), 346–347.
65. [65] Bucciantini, M., Calloni, G., Chiti, F., Formigli, L., Nosi, D., Dobson, C.M., Stefani, M., Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J. Biol. Chem. 279 (2004), 31374–31382.
66. [66] Cecchi, C., Stefani, M., The amyloid-cell membrane system. The interplay between the biophysical features of oligomers/fibrils and cell membrane defines amyloid toxicity. Biophys. Chem. 182 (2013), 30–43.
67. [67] Krebs, M.R., Domike, K.R., Donald, A.M., Protein aggregation: more than just fibrils. Biochem. Soc. Trans. 37 (2009), 682–686.
68. [68] Fodera, V., Zaccone, A., Lattuada, M., Donald, A.M., Electrostatics controls the formation of amyloid superstructures in protein aggregation. Phys. Rev. Lett., 111, 2013, 108105.
69. [69] Vetri, V., Fodera, V., The route to protein aggregate superstructures: Particulates and amyloid-like spherulites. FEBS Lett. 589 (2015), 2448–2463.
70. [70] Foderà, V., Donald, A.M., The formation of amyloid-like superstructures: on the growth of amyloid spherulites. Bionanoimaging, 2014, 301–308 (Chapter 28).
71. [71] Kalhor, H.R., Kamizi, M., Akbari, J., Heydari, A., Inhibition of amyloid formation by ionic liquids: ionic liquids affecting intermediate oligomers. Biomacromolecules 10 (2009), 2468–2475.
72. [72] Sarkar, N., Kumar, M., Dubey, V.K., Rottlerin dissolves pre-formed protein amyloid: a study on hen egg white lysozyme. Biochim. Biophys. Acta 1810 (2011), 809–814.
73. [73] Sarkar, N., Kumar, M., Dubey, V.K., Exploring possibility of promiscuity of amyloid inhibitor: studies on effect of selected compounds on folding and amyloid formation of proteins. Process Biochem. 46 (2011), 1179–1185.
74. [74] Palmal, S., Maity, A.R., Singh, B.K., Basu, S., Jana, N.R., Inhibition of amyloid fibril growth and dissolution of amyloid fibrils by curcumin-gold nanoparticles. Chemistry 20 (2014), 6184–6191.
75. [75] Kim, H.Y., Kim, H.V., Jo, S., Lee, C.J., Choi, S.Y., Kim, D.J., Kim, Y., EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-beta oligomers and plaques. Nat. Commun., 6, 2015, 8997.
76. [76] Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sanchez-Lopez, E., Garcia, M.L., Olloquequi, J., Beas-Zarate, C., Auladell, C., Camins, A., Current research therapeutic strategies for Alzheimer's disease treatment. Neural Plast., 2016, 2016, 8501693.
77. [77] Gautam, S., Karmakar, S., Bose, A., Chowdhury, P.K., beta-cyclodextrin and curcumin, a potent cocktail for disaggregating and/or inhibiting amyloids: a case study with alpha-synuclein. Biochemistry 53 (2014), 4081–4083.
78. [78] Lin, D., Luo, Y., Wu, S., Ma, Q., Wei, G., Yang, X., Investigation of the aggregation process of amyloid-beta-(16-22) peptides and the dissolution of intermediate aggregates. Langmuir 30 (2014), 3170–3175.
79. [79] Krebs, M.R., Macphee, C.E., Miller, A.F., Dunlop, I.E., Dobson, C.M., Donald, A.M., The formation of spherulites by amyloid fibrils of bovine insulin. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 14420–14424.
80. [80] Smith, M.I., Fodera, V., Sharp, J.S., Roberts, C.J., Donald, A.M., Factors affecting the formation of insulin amyloid spherulites. Colloids Surf. B Biointerfaces 89 (2012), 216–222.
81. [81] Martin, J.B., Molecular basis of the neurodegenerative disorders. N. Engl. J. Med. 340 (1999), 1970–1980.
82. [82] Hyman, B.T., Van Hoesen, G.W., Neuron numbers in Alzheimer's disease: cell-specific pathology. Neurobiol. Aging 8 (1987), 555–556.
83. [83] Forno, L.S., Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55 (1996), 259–272.
84. [84] Myers, R.H., Vonsattel, J.P., Paskevich, P.A., Kiely, D.K., Stevens, T.J., Cupples, L.A., Richardson, E.P. Jr., Bird, E.D., Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J. Neuropathol. Exp. Neurol. 50 (1991), 729–742.
85. [85] Hughes, J.T., Pathology of amyotrophic lateral sclerosis. Adv. Neurol. 36 (1982), 61–74.
86. [86] Gray, F., Chretien, F., Adle-Biassette, H., Dorandeu, A., Ereau, T., Delisle, M.B., Kopp, N., Ironside, J.W., Vital, C., Neuronal apoptosis in Creutzfeldt-Jakob disease. J. Neuropathol. Exp. Neurol. 58 (1999), 321–328.
87. [87] Mattson, M.P., Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 1 (2000), 120–129.
88. [88] Reaume, A.G., Elliott, J.L., Hoffman, E.K., Kowall, N.W., Ferrante, R.J., Siwek, D.F., Wilcox, H.M., Flood, D.G., Beal, M.F., Brown, R.H. Jr., Scott, R.W., Snider, W.D., Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 13 (1996), 43–47.
89. [89] Gurney, M.E., Pu, H., Chiu, A.Y., Dal Canto, M.C., Polchow, C.Y., Alexander, D.D., Caliendo, J., Hentati, A., Kwon, Y.W., Deng, H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264 (1994), 1772–1775.
90. [90] Cattaneo, E., Rigamonti, D., Goffredo, D., Zuccato, C., Squitieri, F., Sipione, S., Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci. 24 (2001), 182–188.
91. [91] Martins, V.R., Linden, R., Prado, M.A., Walz, R., Sakamoto, A.C., Izquierdo, I., Brentani, R.R., Cellular prion protein: on the road for functions. FEBS Lett. 512 (2002), 25–28.
92. [92] Kuwahara, C., Takeuchi, A.M., Nishimura, T., Haraguchi, K., Kubosaki, A., Matsumoto, Y., Saeki, K., Yokoyama, T., Itohara, S., Onodera, T., Prions prevent neuronal cell-line death. Nature 400 (1999), 225–226.
93. [93] Mallucci, G.R., Ratte, S., Asante, E.A., Linehan, J., Gowland, I., Jefferys, J.G., Collinge, J., Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J. 21 (2002), 202–210.
94. [94] Loo, D.T., Copani, A., Pike, C.J., Whittemore, E.R., Walencewicz, A.J., Cotman, C.W., Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 7951–7955.
95. [95] Forloni, G., Angeretti, N., Chiesa, R., Monzani, E., Salmona, M., Bugiani, O., Tagliavini, F., Neurotoxicity of a prion protein fragment. Nature 362 (1993), 543–546.
96. [96] Lunkes, A., Mandel, J.L., A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum. Mol. Genet. 7 (1998), 1355–1361.
97. [97] El-Agnaf, O.M., Jakes, R., Curran, M.D., Middleton, D., Ingenito, R., Bianchi, E., Pessi, A., Neill, D., Wallace, A., Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 440 (1998), 71–75.
98. [98] Yan, S.D., Zhu, H., Zhu, A., Golabek, A., Du, H., Roher, A., Yu, J., Soto, C., Schmidt, A.M., Stern, D., Kindy, M., Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med. 6 (2000), 643–651.
99. [99] Cummings, C.J., Mancini, M.A., Antalffy, B., DeFranco, D.B., Orr, H.T., Zoghbi, H.Y., Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 19 (1998), 148–154.
100. [100] Ii, K., Ito, H., Tanaka, K., Hirano, A., Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J. Neuropathol. Exp. Neurol. 56 (1997), 125–131.
101. [101] Arispe, N., Rojas, E., Pollard, H.B., Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 567–571.
102. [102] Lin, M.C., Mirzabekov, T., Kagan, B.L., Channel formation by a neurotoxic prion protein fragment. J. Biol. Chem. 272 (1997), 44–47.
103. [103] Behl, C., Davis, J.B., Lesley, R., Schubert, D., Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77 (1994), 817–827.
104. [104] Hsu, L.J., Sagara, Y., Arroyo, A., Rockenstein, E., Sisk, A., Mallory, M., Wong, J., Takenouchi, T., Hashimoto, M., Masliah, E., alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157 (2000), 401–410.
105. [105] Wyss-Coray, T., Mucke, L., Inflammation in neurodegenerative disease–a double-edged sword. Neuron 35 (2002), 419–432.
106. [106] Sapp, E., Kegel, K.B., Aronin, N., Hashikawa, T., Uchiyama, Y., Tohyama, K., Bhide, P.G., Vonsattel, J.P., DiFiglia, M., Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 60 (2001), 161–172.
107. [107] Muhleisen, H., Gehrmann, J., Meyermann, R., Reactive microglia in Creutzfeldt-Jakob disease. Neuropathol. Appl. Neurobiol. 21 (1995), 505–517.
108. [108] McGeer, P.L., McGeer, E.G., The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 21 (1995), 195–218.
109. [109] Xia, M.Q., Hyman, B.T., Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J. Neurovirol. 5 (1999), 32–41.
110. [110] Yates, S.L., Burgess, L.H., Kocsis-Angle, J., Antal, J.M., Dority, M.D., Embury, P.B., Piotrkowski, A.M., Brunden, K.R., Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia. J. Neurochem. 74 (2000), 1017–1025.
111. [111] McGeer, P.L., Schulzer, M., McGeer, E.G., Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47 (1996), 425–432.
112. [112] Pedersen, J.T., Heegaard, N.H., Analysis of protein aggregation in neurodegenerative disease. Anal. Chem. 85 (2013), 4215–4227.
113. [113] Munishkina, L.A., Fink, A.L., Fluorescence as a method to reveal structures and membrane-interactions of amyloidogenic proteins. Biochim. Biophys. Acta 1768 (2007), 1862–1885.
114. [114] Bartolini, M., Bertucci, C., Bolognesi, M.L., Cavalli, A., Melchiorre, C., Andrisano, V., Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. Chembiochem 8 (2007), 2152–2161.
115. [115] Ulrih, N.P., Barry, C.H., Fink, A.L., Impact of Tyr to Ala mutations on alpha-synuclein fibrillation and structural properties. Biochim. Biophys. Acta 1782 (2008), 581–585.
116. [116] Terzi, E., Holzemann, G., Seelig, J., Self-association of beta-amyloid peptide (1-40) in solution and binding to lipid membranes. J. Mol. Biol. 252 (1995), 633–642.
117. [117] Middleton, D.A., Solid-state NMR spectroscopy as a tool for drug design: from membrane-embedded targets to amyloid fibrils. Biochem. Soc. Trans. 35 (2007), 985–990.
118. [118] Salmona, M., Morbin, M., Massignan, T., Colombo, L., Mazzoleni, G., Capobianco, R., Diomede, L., Thaler, F., Mollica, L., Musco, G., Kourie, J.J., Bugiani, O., Sharma, D., Inouye, H., Kirschner, D.A., Forloni, G., Tagliavini, F., Structural properties of Gerstmann-Straussler-Scheinker disease amyloid protein. J. Biol. Chem. 278 (2003), 48146–48153.
119. [119] Natalello, A., Prokorov, V.V., Tagliavini, F., Morbin, M., Forloni, G., Beeg, M., Manzoni, C., Colombo, L., Gobbi, M., Salmona, M., Doglia, S.M., Conformational plasticity of the Gerstmann-Straussler-Scheinker disease peptide as indicated by its multiple aggregation pathways. J. Mol. Biol. 381 (2008), 1349–1361.
120. [120] Inestrosa, N.C., Alvarez, A., Dinamarca, M.C., Perez-Acle, T., Colombres, M., Acetylcholinesterase-amyloid-beta-peptide interaction: effect of Congo Red and the role of the Wnt pathway. Curr. Alzheimer Res. 2 (2005), 301–306.
121. [121] Frid, P., Anisimov, S.V., Popovic, N., Congo red and protein aggregation in neurodegenerative diseases. Brain Res. Rev. 53 (2007), 135–160.
122. [122] LeVine, H. 3rd, Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2 (1993), 404–410.
123. [123] Nilsson, M.R., Techniques to study amyloid fibril formation in vitro. Methods 34 (2004), 151–160.
124. [124] Groenning, M., Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils-current status. J. Chem. Biol. 3 (2010), 1–18.
125. [125] Mahler, H.C., Friess, W., Grauschopf, U., Kiese, S., Protein aggregation: pathways, induction factors and analysis. J. Pharm. Sci. 98 (2009), 2909–2934.
126. [126] Harper, J.D., Lansbury, P.T. Jr., Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66 (1997), 385–407.
127. [127] Lomakin, A., Chung, D.S., Benedek, G.B., Kirschner, D.A., Teplow, D.B., On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 1125–1129.
128. [128] Lomakin, A., Teplow, D.B., Quasielastic light scattering study of amyloid beta-protein fibrillogenesis. Methods Mol. Biol. 849 (2012), 69–83.
129. [129] Yamin, G., Glaser, C.B., Uversky, V.N., Fink, A.L., Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. J. Biol. Chem. 278 (2003), 27630–27635.
130. [130] Georgalis, Y., Starikov, E.B., Hollenbach, B., Lurz, R., Scherzinger, E., Saenger, W., Lehrach, H., Wanker, E.E., Huntingtin aggregation monitored by dynamic light scattering. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 6118–6121.
131. [131] van den Heuvel, R.H., Heck, A.J., Native protein mass spectrometry: from intact oligomers to functional machineries. Curr. Opin. Chem. Biol. 8 (2004), 519–526.
132. [132] Heck, A.J., Van Den Heuvel, R.H., Investigation of intact protein complexes by mass spectrometry. Mass Spectrom. Rev. 23 (2004), 368–389.
133. [133] Stellato, F., Menestrina, G., Serra, M.D., Potrich, C., Tomazzolli, R., Meyer-Klaucke, W., Morante, S., Metal binding in amyloid beta-peptides shows intra- and inter-peptide coordination modes. Eur. Biophys. J. 35 (2006), 340–351.
134. [134] Del Mar, C., Greenbaum, E.A., Mayne, L., Englander, S.W., Woods, V.L. Jr., Structure and properties of alpha-synuclein and other amyloids determined at the amino acid level. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 15477–15482.
135. [135] Vilar, M., Chou, H.T., Luhrs, T., Maji, S.K., Riek-Loher, D., Verel, R., Manning, G., Stahlberg, H., Riek, R., The fold of alpha-synuclein fibrils. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 8637–8642.
136. [136] Carulla, N., Caddy, G.L., Hall, D.R., Zurdo, J., Gairi, M., Feliz, M., Giralt, E., Robinson, C.V., Dobson, C.M., Molecular recycling within amyloid fibrils. Nature 436 (2005), 554–558.
137. [137] Carulla, N., Zhou, M., Giralt, E., Robinson, C.V., Dobson, C.M., Structure and intermolecular dynamics of aggregates populated during amyloid fibril formation studied by hydrogen/deuterium exchange. Acc. Chem. Res. 43 (2010), 1072–1079.
138. [138] Xu, S., Cross-beta-sheet structure in amyloid fiber formation. J. Phys. Chem. B 113 (2009), 12447–12455.
139. [139] Krebs, M.R., Devlin, G.L., Donald, A.M., Amyloid fibril-like structure underlies the aggregate structure across the pH range for beta-lactoglobulin. Biophys. J. 96 (2009), 5013–5019.
140. [140] Jeganathan, S., von Bergen, M., Mandelkow, E.M., Mandelkow, E., The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments. Biochemistry 47 (2008), 10526–10539.
141. [141] Kayed, R., Bernhagen, J., Greenfield, N., Sweimeh, K., Brunner, H., Voelter, W., Kapurniotu, A., Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro. J. Mol. Biol. 287 (1999), 781–796.
142. [142] Bladen, H.A., Nylen, M.U., Glenner, G.G., The ultrastructure of human amyloid as revealed by the negative staining technique. J. Ultrastruct. Res. 14 (1966), 449–459.
143. [143] Cohen, A.S., Calkins, E., Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 183 (1959), 1202–1203.
144. [144] Lashuel, H.A., Wall, J.S., Molecular electron microscopy approaches to elucidating the mechanisms of protein fibrillogenesis. Methods Mol. Biol. 299 (2005), 81–101.
145. [145] Nichols, M.R., Moss, M.A., Reed, D.K., Hoh, J.H., Rosenberry, T.L., Rapid assembly of amyloid-beta peptide at a liquid/liquid interface produces unstable beta-sheet fibers. Biochemistry 44 (2005), 165–173.
146. [146] Manno, M., Craparo, E.F., Podesta, A., Bulone, D., Carrotta, R., Martorana, V., Tiana, G., San Biagio, P.L., Kinetics of different processes in human insulin amyloid formation. J. Mol. Biol. 366 (2007), 258–274.
147. [147] Goldsbury, C., Green, J., Time-lapse atomic force microscopy in the characterization of amyloid-like fibril assembly and oligomeric intermediates. Methods Mol. Biol. 299 (2005), 103–128.
148. [148] Gosal, W.S., Myers, S.L., Radford, S.E., Thomson, N.H., Amyloid under the atomic force microscope. Protein Pept. Lett. 13 (2006), 261–270.
149. [149] Serem, W.K., Bett, C.K., Ngunjiri, J.N., Garno, J.C., Studies of the growth, evolution, and self-aggregation of beta-amyloid fibrils using tapping-mode atomic force microscopy. Microsc. Res. Tech. 74 (2011), 699–708.
150. [150] Colombo, R., Carotti, A., Catto, M., Racchi, M., Lanni, C., Verga, L., Caccialanza, G., De Lorenzi, E., CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity. Electrophoresis 30 (2009), 1418–1429.
151. [151] Ferrao-Gonzales, A.D., Robbs, B.K., Moreau, V.H., Ferreira, A., Juliano, L., Valente, A.P., Almeida, F.C., Silva, J.L., Foguel, D., Controlling {beta}-amyloid oligomerization by the use of naphthalene sulfonates: trapping low molecular weight oligomeric species. J. Biol. Chem. 280 (2005), 34747–34754.
152. [152] Brown, P.H., Balbo, A., Schuck, P., Characterizing protein-protein interactions by sedimentation velocity analytical ultracentrifugation. Curr. Protoc. Immunol., Chapter 18, 2008 Unit 18 15.
153. [153] 2010Alzheimer's disease facts and figures. Alzheimers Dement. 6 (2010), 158–194.
154. [154] Centers for Disease Control and Prevention and The Merck Company Foundation, The State of Health and Aging in America Merck Company Foundation. 2007, Whitehouse Station, New Jersey, USA.
155. [155] 2009Alzheimer's disease facts and figures. Alzheimers Dement. 5 (2009), 234–270.
156. [156] Ferri, C.P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., Jorm, A., Mathers, C., Menezes, P.R., Rimmer, E., Scazufca, M., Global prevalence of dementia: a Delphi consensus study. Lancet 366 (2005), 2112–2117.
157. [157] Denny, R.A., Gavrin, L.K., Saiah, E., Recent developments in targeting protein misfolding diseases. Bioorg Med. Chem. Lett. 23 (2013), 1935–1944.
158. [158] Hard, T., Lendel, C., Inhibition of amyloid formation. J. Mol. Biol. 421 (2012), 441–465.
159. [159] Bartolini, M., Andrisano, V., Strategies for the inhibition of protein aggregation in human diseases. Chembiochem 11 (2010), 1018–1035.
160. [160] Miroy, G.J., Lai, Z., Lashuel, H.A., Peterson, S.A., Strang, C., Kelly, J.W., Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 15051–15056.
161. [161] Connelly, S., Choi, S., Johnson, S.M., Kelly, J.W., Wilson, I.A., Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr. Opin. Struct. Biol. 20 (2010), 54–62.
162. [162] Hammarstrom, P., Schneider, F., Kelly, J.W., Trans-suppression of misfolding in an amyloid disease. Science 293 (2001), 2459–2462.
163. [163] Gavrin, L.K., Denny, R.A., Saiah, E., Small molecules that target protein misfolding. J. Med. Chem. 55 (2012), 10823–10843.
164. [164] Tatzelt, J., Prusiner, S.B., Welch, W.J., Chemical chaperones interfere with the formation of scrapie prion protein. EMBO J. 15 (1996), 6363–6373.
165. [165] Cohen, F.E., Kelly, J.W., Therapeutic approaches to protein-misfolding diseases. Nature 426 (2003), 905–909.
166. [166] Morello, J.P., Salahpour, A., Laperriere, A., Bernier, V., Arthus, M.F., Lonergan, M., Petaja-Repo, U., Angers, S., Morin, D., Bichet, D.G., Bouvier, M., Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Investig. 105 (2000), 887–895.
167. [167] Ray, S.S., Nowak, R.J., Brown, R.H. Jr., Lansbury, P.T. Jr., Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 3639–3644.
168. [168] Nowak, R.J., Cuny, G.D., Choi, S., Lansbury, P.T., Ray, S.S., Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. J. Med. Chem. 53 (2010), 2709–2718.
169. [169] Ferraiuolo, L., Kirby, J., Grierson, A.J., Sendtner, M., Shaw, P.J., Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 7 (2011), 616–630.
170. [170] Pepys, M.B., Hawkins, P.N., Booth, D.R., Vigushin, D.M., Tennent, G.A., Soutar, A.K., Totty, N., Nguyen, O., Blake, C.C., Terry, C.J., et al. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 362 (1993), 553–557.
171. [171] Dumoulin, M., Last, A.M., Desmyter, A., Decanniere, K., Canet, D., Larsson, G., Spencer, A., Archer, D.B., Sasse, J., Muyldermans, S., Wyns, L., Redfield, C., Matagne, A., Robinson, C.V., Dobson, C.M., A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature 424 (2003), 783–788.
172. [172] Sciarretta, K.L., Gordon, D.J., Meredith, S.C., Peptide-based inhibitors of amyloid assembly. Methods Enzymol. 413 (2006), 273–312.
173. [173] Soto, C., Sigurdsson, E.M., Morelli, L., Kumar, R.A., Castano, E.M., Frangione, B., Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med. 4 (1998), 822–826.
174. [174] Permanne, B., Adessi, C., Saborio, G.P., Fraga, S., Frossard, M.J., Van Dorpe, J., Dewachter, I., Banks, W.A., Van Leuven, F., Soto, C., Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J. 16 (2002), 860–862.
175. [175] Soto, C., Kascsak, R.J., Saborio, G.P., Aucouturier, P., Wisniewski, T., Prelli, F., Kascsak, R., Mendez, E., Harris, D.A., Ironside, J., Tagliavini, F., Carp, R.I., Frangione, B., Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 355 (2000), 192–197.
176. [176] El-Agnaf, O.M., Paleologou, K.E., Greer, B., Abogrein, A.M., King, J.E., Salem, S.A., Fullwood, N.J., Benson, F.E., Hewitt, R., Ford, K.J., Martin, F.L., Harriott, P., Cookson, M.R., Allsop, D., A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J. 18 (2004), 1315–1317.
177. [177] Gibson, T.J., Murphy, R.M., Inhibition of insulin fibrillogenesis with targeted peptides. Protein Sci. 15 (2006), 1133–1141.
178. [178] Chabry, J., Caughey, B., Chesebro, B., Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J. Biol. Chem. 273 (1998), 13203–13207.
179. [179] Porat, Y., Mazor, Y., Efrat, S., Gazit, E., Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. Biochemistry 43 (2004), 14454–14462.
180. [180] Tjernberg, L.O., Naslund, J., Lindqvist, F., Johansson, J., Karlstrom, A.R., Thyberg, J., Terenius, L., Nordstedt, C., Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 271 (1996), 8545–8548.
181. [181] Gordon, D.J., Tappe, R., Meredith, S.C., Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits Abeta1-40 fibrillogenesis. J. Pept. Res. 60 (2002), 37–55.
182. [182] Hughes, E., Burke, R.M., Doig, A.J., Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation. J. Biol. Chem. 275 (2000), 25109–25115.
183. [183] Kokkoni, N., Stott, K., Amijee, H., Mason, J.M., Doig, A.J., N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure. Biochemistry 45 (2006), 9906–9918.
184. [184] Madine, J., Doig, A.J., Middleton, D.A., Design of an N-methylated peptide inhibitor of alpha-synuclein aggregation guided by solid-state NMR. J. Am. Chem. Soc. 130 (2008), 7873–7881.
185. [185] Aguzzi, A., Glatzel, M., Montrasio, F., Prinz, M., Heppner, F.L., Interventional strategies against prion diseases. Nat. Rev. Neurosci. 2 (2001), 745–749.
186. [186] Sacchettini, J.C., Kelly, J.W., Therapeutic strategies for human amyloid diseases. Nat. Rev. Drug Discov. 1 (2002), 267–275.
187. [187] LeVine, H., The challenge of inhibiting Abeta polymerization. Curr. Med. Chem. 9 (2002), 1121–1133.
188. [188] Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., Seubert, P., Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999), 173–177.
189. [189] Morgan, D., Diamond, D.M., Gottschall, P.E., Ugen, K.E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M., Arendash, G.W., A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000), 982–985.
190. [190] Janus, C., Pearson, J., McLaurin, J., Mathews, P.M., Jiang, Y., Schmidt, S.D., Chishti, M.A., Horne, P., Heslin, D., French, J., Mount, H.T., Nixon, R.A., Mercken, M., Bergeron, C., Fraser, P.E., St George-Hyslop, P., Westaway, D., A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000), 979–982.
191. [191] Sigurdsson, E.M., Brown, D.R., Daniels, M., Kascsak, R.J., Kascsak, R., Carp, R., Meeker, H.C., Frangione, B., Wisniewski, T., Immunization delays the onset of prion disease in mice. Am. J. Pathol. 161 (2002), 13–17.
192. [192] White, A.R., Enever, P., Tayebi, M., Mushens, R., Linehan, J., Brandner, S., Anstee, D., Collinge, J., Hawke, S., Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422 (2003), 80–83.
193. [193] Heppner, F.L., Musahl, C., Arrighi, I., Klein, M.A., Rulicke, T., Oesch, B., Zinkernagel, R.M., Kalinke, U., Aguzzi, A., Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294 (2001), 178–182.
194. [194] Emadi, S., Liu, R., Yuan, B., Schulz, P., McAllister, C., Lyubchenko, Y., Messer, A., Sierks, M.R., Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 43 (2004), 2871–2878.
195. [195] Emadi, S., Barkhordarian, H., Wang, M.S., Schulz, P., Sierks, M.R., Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J. Mol. Biol. 368 (2007), 1132–1144.
196. [196] Khoshnan, A., Ko, J., Patterson, P.H., Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 1002–1007.
197. [197] Wolfgang, W.J., Miller, T.W., Webster, J.M., Huston, J.S., Thompson, L.M., Marsh, J.L., Messer, A., Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 11563–11568.
198. [198] Asuni, A.A., Boutajangout, A., Quartermain, D., Sigurdsson, E.M., Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27 (2007), 9115–9129.
199. [199] Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., Rosenmann, H., Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol. 224 (2010), 472–485.
200. [200] Gong, Y., Chang, L., Viola, K.L., Lacor, P.N., Lambert, M.P., Finch, C.E., Krafft, G.A., Klein, W.L., Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 10417–10422.
201. [201] Lambert, M.P., Viola, K.L., Chromy, B.A., Chang, L., Morgan, T.E., Yu, J., Venton, D.L., Krafft, G.A., Finch, C.E., Klein, W.L., Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79 (2001), 595–605.
202. [202] O'Nuallain, B., Hrncic, R., Wall, J.S., Weiss, D.T., Solomon, A., Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J. Immunol. 176 (2006), 7071–7078.
203. [203] Lindhagen-Persson, M., Brannstrom, K., Vestling, M., Steinitz, M., Olofsson, A., Amyloid-beta oligomer specificity mediated by the IgM isotype–implications for a specific protective mechanism exerted by endogenous auto-antibodies. PLoS One, 5, 2010, e13928.
204. [204] Yanamandra, K., Gruden, M.A., Casaite, V., Meskys, R., Forsgren, L., Morozova-Roche, L.A., alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One, 6, 2011, e18513.
205. [205] O'Nuallain, B., Acero, L., Williams, A.D., Koeppen, H.P., Weber, A., Schwarz, H.P., Wall, J.S., Weiss, D.T., Solomon, A., Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry 47 (2008), 12254–12256.
206. [206] O'Nuallain, B., Williams, A.D., McWilliams-Koeppen, H.P., Acero, L., Weber, A., Ehrlich, H., Schwarz, H.P., Solomon, A., Anti-amyloidogenic activity of IgGs contained in normal plasma. J. Clin. Immunol. 30:Suppl. 1 (2010), S37–S42.
207. [207] Adekar, S.P., Klyubin, I., Macy, S., Rowan, M.J., Solomon, A., Dessain, S.K., O'Nuallain, B., Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chains. J. Biol. Chem. 285 (2010), 1066–1074.
208. [208] Geylis, V., Kourilov, V., Meiner, Z., Nennesmo, I., Bogdanovic, N., Steinitz, M., Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol. Aging 26 (2005), 597–606.
209. [209] Neff, F., Wei, X., Nolker, C., Bacher, M., Du, Y., Dodel, R., Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun. Rev. 7 (2008), 501–507.
210. [210] Rosenmann, H., Meiner, Z., Geylis, V., Abramsky, O., Steinitz, M., Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci. Lett. 410 (2006), 90–93.
211. [211] Relkin, N.R., Szabo, P., Adamiak, B., Burgut, T., Monthe, C., Lent, R.W., Younkin, S., Younkin, L., Schiff, R., Weksler, M.E., 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 30 (2009), 1728–1736.
212. [212] Dodel, R.C., Du, Y., Depboylu, C., Hampel, H., Frolich, L., Haag, A., Hemmeter, U., Paulsen, S., Teipel, S.J., Brettschneider, S., Spottke, A., Nolker, C., Moller, H.J., Wei, X., Farlow, M., Sommer, N., Oertel, W.H., Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75 (2004), 1472–1474.
213. [213] Cardinale, A., Biocca, S., The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases. Trends Mol. Med. 14 (2008), 373–380.
214. [214] Masliah, E., Rockenstein, E., Mante, M., Crews, L., Spencer, B., Adame, A., Patrick, C., Trejo, M., Ubhi, K., Rohn, T.T., Mueller-Steiner, S., Seubert, P., Barbour, R., McConlogue, L., Buttini, M., Games, D., Schenk, D., Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One, 6, 2011, e19338.
215. [215] Castellani, R.J., Rolston, R.K., Smith, M.A., Alzheimer disease. Dis. Mon. 56 (2010), 484–546.
216. [216] Hong-Qi, Y., Zhi-Kun, S., Sheng-Di, C., Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Abeta and tau. Transl. Neurodegener., 1, 2012, 21.
217. [217] Roberson, E.D., Mucke, L., 100 years and counting: prospects for defeating Alzheimer's disease. Science 314 (2006), 781–784.
218. [218] Sharma, A., Bemis, M., Desilets, A.R., Role of medium chain triglycerides (Axona(R)) in the treatment of mild to moderate Alzheimer's disease. Am. J. Alzheimers Dis. Other Dement. 29 (2014), 409–414.
219. [219] Jankovic, J., Levodopa strengths and weaknesses. Neurology 58 (2002), S19–S32.
220. [220] Korczyn, A.D., Brunt, E.R., Larsen, J.P., Nagy, Z., Poewe, W.H., Ruggieri, S., A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 53 (1999), 364–370.
221. [221] Ondo, W., Hunter, C., Almaguer, M., Gancher, S., Jankovic, J., Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin. Neuropharmacol. 22 (1999), 1–4.
222. [222] Jankovic, J., Watts, R.L., Martin, W., Boroojerdi, B., Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch. Neurol. 64 (2007), 676–682.
223. [223] Davies, S., Ramsden, D.B., Huntington's disease. Mol. Pathol. 54 (2001), 409–413.
224. [224] Frank, S., Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr. Dis. Treat. 6 (2010), 657–665.
225. [225] Kanning, K.C., Kaplan, A., Henderson, C.E., Motor neuron diversity in development and disease. Annu. Rev. Neurosci. 33 (2010), 409–440.
226. [226] Lamanauskas, N., Nistri, A., Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur. J. Neurosci. 27 (2008), 2501–2514.
227. [227] Ludolph, A.C., Jesse, S., Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials. Ther. Adv. Neurol. Disord. 2 (2009), 319–326.
228. [228] V. Kumar, A. Islam, M.I. Hassan, F. Ahmad, Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning, Eur. J. Med. Chem. http://dx.doi.org/10.1016/j.ejmech.2016.06.017.
229. [229] Basu Baul, T.S., Kundu, S., Singh, P., Shaveta, Guedes da Silva, M.F., Insight into inhibition of the human amyloid beta protein precursor (APP: PDB ID ) using (E)-N-(pyridin-2-ylmethylene)arylamine (LR) models: structure elucidation of a family of ZnX2-LR complexes. Dalton Trans. 44 (2015), 2359–2369.
230. [230] Barnwell, E., Padmaraju, V., Baranello, R., Pacheco-Quinto, J., Crosson, C., Ablonczy, Z., Eckman, E., Eckman, C.B., Ramakrishnan, V., Greig, N.H., Pappolla, M.A., Sambamurti, K., Evidence of a novel mechanism for partial gamma-secretase inhibition induced paradoxical increase in secreted amyloid beta protein. PLoS One, 9, 2014, e91531.
231. [231] Thomas, R.S., Hvoslef-Eide, M., Good, M.A., Kidd, E.J., Inhibition of amyloid-beta production by anti-amyloid precursor protein antibodies in primary mouse cortical neurones. Neuroreport 24 (2013), 1058–1061.
232. [232] Urano, Y., Ochiai, S., Noguchi, N., Suppression of amyloid-beta production by 24S-hydroxycholesterol via inhibition of intracellular amyloid precursor protein trafficking. FASEB J. 27 (2013), 4305–4315.
233. [233] Parr, C., Carzaniga, R., Gentleman, S.M., Van Leuven, F., Walter, J., Sastre, M., Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-beta precursor protein. Mol. Cell Biol. 32 (2012), 4410–4418.
234. [234] Wang, X., Takata, T., Bai, X., Ou, F., Yokono, K., Sakurai, T., Pyruvate prevents the inhibition of the long-term potentiation induced by amyloid-beta through protein phosphatase 2A inactivation. J. Alzheimers Dis. 30 (2012), 665–673.
235. [235] Zeng, K.W., Ko, H., Yang, H.O., Wang, X.M., Icariin attenuates beta-amyloid-induced neurotoxicity by inhibition of tau protein hyperphosphorylation in PC12 cells. Neuropharmacology 59 (2010), 542–550.
236. [236] Anand, K., Sabbagh, M., Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs, 2015, 1–6.
237. [237] Leyk, J., Goldbaum, O., Noack, M., Richter-Landsberg, C., Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance. J. Mol. Neurosci. 55 (2015), 1031–1046.
238. [238] Cisek, K., Cooper, G.L., Huseby, C.J., Kuret, J., Structure and mechanism of action of tau aggregation inhibitors. Curr. Alzheimer Res. 11 (2014), 918–927.
239. [239] Zhou, F., Chen, S., Sun, X., Research progress of abnormal phosphorylation of microtubule-associated tau protein and of the targeted inhibition of the phosphorylation. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 29 (2012), 788–792.
240. [240] Zhang, Z., Zhao, R., Qi, J., Wen, S., Tang, Y., Wang, D., Inhibition of glycogen synthase kinase-3beta by Angelica sinensis extract decreases beta-amyloid-induced neurotoxicity and tau phosphorylation in cultured cortical neurons. J. Neurosci. Res. 89 (2011), 437–447.
241. [241] Bachhuber, T., Katzmarski, N., McCarter, J.F., Loreth, D., Tahirovic, S., Kamp, F., Abou-Ajram, C., Nuscher, B., Serrano-Pozo, A., Muller, A., Prinz, M., Steiner, H., Hyman, B.T., Haass, C., Meyer-Luehmann, M., Inhibition of amyloid-beta plaque formation by alpha-synuclein. Nat. Med. 21 (2015), 802–807.
242. [242] Daher, J.P., Abdelmotilib, H.A., Hu, X., Volpicelli-Daley, L.A., Moehle, M.S., Fraser, K.B., Needle, E., Chen, Y., Steyn, S.J., Galatsis, P., Hirst, W.D., West, A.B., Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates alpha-synuclein gene-induced neurodegeneration. J. Biol. Chem. 290 (2015), 19433–19444.
243. [243] Hebron, M.L., Lonskaya, I., Moussa, C.E., Tyrosine kinase inhibition facilitates autophagic SNCA/alpha-synuclein clearance. Autophagy 9 (2013), 1249–1250.
244. [244] Devine, M.J., Proteasomal inhibition as a treatment strategy for Parkinson's disease: the impact of alpha-synuclein on Nurr1. J. Neurosci. 32 (2012), 16071–16073.
245. [245] Bruinsma, I.B., Bruggink, K.A., Kinast, K., Versleijen, A.A., Segers-Nolten, I.M., Subramaniam, V., Kuiperij, H.B., Boelens, W., de Waal, R.M., Verbeek, M.M., Inhibition of alpha-synuclein aggregation by small heat shock proteins. Proteins 79 (2011), 2956–2967.
246. [246] Caruana, M., Hogen, T., Levin, J., Hillmer, A., Giese, A., Vassallo, N., Inhibition and disaggregation of alpha-synuclein oligomers by natural polyphenolic compounds. FEBS Lett. 585 (2011), 1113–1120.
247. [247] Jia, H., Morris, C.D., Williams, R.M., Loring, J.F., Thomas, E.A., HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E56–E64.
248. [248] Kim, S., Kim, K.T., Therapeutic approaches for inhibition of protein aggregation in Huntington's disease. Exp. Neurobiol. 23 (2014), 36–44.
249. [249] Chaudhary, R.K., Kardani, J., Singh, K., Banerjee, R., Roy, I., Deciphering the roles of trehalose and Hsp104 in the inhibition of aggregation of mutant huntingtin in a yeast model of Huntington's disease. Neuromol. Med. 16 (2014), 280–291.
250. [250] Yuen, E.Y., Wei, J., Zhong, P., Yan, Z., Disrupted GABAAR trafficking and synaptic inhibition in a mouse model of Huntington's disease. Neurobiol. Dis. 46 (2012), 497–502.
251. [251] Tonges, L., Gunther, R., Suhr, M., Jansen, J., Balck, A., Saal, K.A., Barski, E., Nientied, T., Gotz, A.A., Koch, J.C., Mueller, B.K., Weishaupt, J.H., Sereda, M.W., Hanisch, U.K., Bahr, M., Lingor, P., Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia 62 (2014), 217–232.
252. [252] Xia, G., Benmohamed, R., Kim, J., Arvanites, A.C., Morimoto, R.I., Ferrante, R.J., Kirsch, D.R., Silverman, R.B., Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis. J. Med. Chem. 54 (2011), 2409–2421.
253. [253] Reddy, L.V., Miller, T.M., RNA-targeted therapeutics for ALS. Neurotherapeutics 12 (2015), 424–427.
254. [254] Kim, J., Kim, T.Y., Cho, K.S., Kim, H.N., Koh, J.Y., Autophagy activation and neuroprotection by progesterone in the G93A-SOD1 transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 59 (2013), 80–85.
255. [255] Huang, Y.C., Lin, K.F., He, R.Y., Tu, P.H., Koubek, J., Hsu, Y.C., Huang, J.J., Inhibition of TDP-43 aggregation by nucleic acid binding. PLoS One, 8, 2013, e64002.
256. [256] Song, Y., Nagy, M., Ni, W., Tyagi, N.K., Fenton, W.A., Lopez-Giraldez, F., Overton, J.D., Horwich, A.L., Brady, S.T., Molecular chaperone Hsp110 rescues a vesicle transport defect produced by an ALS-associated mutant SOD1 protein in squid axoplasm. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 5428–5433.
257. [257] Rabinovich-Toidman, P., Becker, M., Barbiro, B., Solomon, B., Inhibition of amyloid precursor protein beta-secretase cleavage site affects survival and motor functions of amyotrophic lateral sclerosis transgenic mice. Neurodegener. Dis. 10 (2012), 30–33.
258. [258] Zheng, M., Shi, Y., Fan, D., Nuclear TAR DNA-binding protein 43: a new target for amyotrophic lateral sclerosis treatment. Neural Regen. Res. 8 (2013), 3284–3295.
259. [259] Pagadala, N.S., Perez-Pineiro, R., Wishart, D.S., Tuszynski, J.A., In silico studies and fluorescence binding assays of potential anti-prion compounds reveal an important binding site for prion inhibition from PrP(C) to PrP(Sc). Eur. J. Med. Chem. 91 (2015), 118–131.
260. [260] Baral, P.K., Swayampakula, M., Rout, M.K., Kav, N.N., Spyracopoulos, L., Aguzzi, A., James, M.N., Structural basis of prion inhibition by phenothiazine compounds. Structure 22 (2014), 291–303.
261. [261] Zeymer, C., Werbeck, N.D., Schlichting, I., Reinstein, J., The molecular mechanism of Hsp100 chaperone inhibition by the prion curing agent guanidinium chloride. J. Biol. Chem. 288 (2013), 7065–7076.
262. [262] Last, V., Williams, A., Werling, D., Inhibition of cytosolic Phospholipase A2 prevents prion peptide-induced neuronal damage and co-localisation with Beta III Tubulin. BMC Neurosci., 13, 2012, 106.
263. [263] Mays, C.E., Joy, S., Li, L., Yu, L., Genovesi, S., West, F.G., Westaway, D., Prion inhibition with multivalent PrPSc binding compounds. Biomaterials 33 (2012), 6808–6822.
264. [264] Chang, J., Yang, L., Kouadir, M., Peng, Y., Zhang, S., Shi, F., Zhou, X., Yin, X., Zhao, D., Antibody-mediated inhibition of integrin alpha5beta1 blocks neurotoxic prion peptide PrP106-126-induced activation of BV2 microglia. J. Mol. Neurosci. 48 (2012), 248–252.
265. [265] Guichard, C., Ivanyi-Nagy, R., Sharma, K.K., Gabus, C., Marc, D., Mely, Y., Darlix, J.L., Analysis of nucleic acid chaperoning by the prion protein and its inhibition by oligonucleotides. Nucleic Acids Res. 39 (2011), 8544–8558.
266. [266] Mukherjee, A., Morales-Scheihing, D., Gonzalez-Romero, D., Green, K., Taglialatela, G., Soto, C., Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survival. PLoS Pathog., 6, 2010, e1001138.
267. [267] Lim, Y.B., Mays, C.E., Kim, Y., Titlow, W.B., Ryou, C., The inhibition of prions through blocking prion conversion by permanently charged branched polyamines of low cytotoxicity. Biomaterials 31 (2010), 2025–2033.
268. [268] Groop, P.H., Cooper, M.E., Perkovic, V., Sharma, K., Schernthaner, G., Haneda, M., Hocher, B., Gordat, M., Cescutti, J., Woerle, H.J., von Eynatten, M., Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: rationale and design of the MARLINA-T2D trial. Diab Vasc. Dis. Res. 12 (2015), 455–462.
269. [269] Tatosian, D.A., Guo, Y., Schaeffer, A.K., Gaibu, N., Popa, S., Stoch, A., Langdon, R.B., Kauh, E.A., Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Ther. 4 (2013), 431–442.
270. [270] Kilov, G., Leow, S., Thomas, M., SGLT2 inhibition with dapagliflozin – a novel approach for the management of type 2 diabetes. Aust. Fam. Physician 42 (2013), 706–710.
271. [271] Huisamen, B., Cyclic AMP and PKA: how can a lot of good come from the potentially bad? : editorial to: “phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus” by Y. Birnbaum et al. Cardiovasc. Drugs Ther. 26 (2012), 435–436.
272. [272] Bourgault, S., Choi, S., Buxbaum, J.N., Kelly, J.W., Price, J.L., Reixach, N., Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem. Biophys. Res. Commun. 410 (2011), 707–713.
273. [273] Vilaro, M., Nieto, J., La Parra, J.R., Almeida, M.R., Ballesteros, A., Planas, A., Arsequell, G., Valencia, G., Tuning transthyretin amyloidosis inhibition properties of iododiflunisal by combinatorial engineering of the nonsalicylic ring substitutions. ACS Comb. Sci. 17 (2015), 32–38.
274. [274] Li, X., Zhang, X., Ladiwala, A.R., Du, D., Yadav, J.K., Tessier, P.M., Wright, P.E., Kelly, J.W., Buxbaum, J.N., Mechanisms of transthyretin inhibition of beta-amyloid aggregation in vitro. J. Neurosci. 33 (2013), 19423–19433.
275. [275] Sant'anna, R.O., Braga, C.A., Polikarpov, I., Ventura, S., Lima, L.M., Foguel, D., Inhibition of human transthyretin aggregation by non-steroidal anti-inflammatory compounds: a structural and thermodynamic analysis. Int. J. Mol. Sci. 14 (2013), 5284–5311.
276. [276] Ferreira, N., Santos, S.A., Domingues, M.R., Saraiva, M.J., Almeida, M.R., Dietary curcumin counteracts extracellular transthyretin deposition: insights on the mechanism of amyloid inhibition. Biochim. Biophys. Acta 1832 (2013), 39–45.
277. [277] Ozawa, D., Hasegawa, K., Lee, Y.H., Sakurai, K., Yanagi, K., Ookoshi, T., Goto, Y., Naiki, H., Inhibition of beta2-microglobulin amyloid fibril formation by alpha2-macroglobulin. J. Biol. Chem. 286 (2011), 9668–9676.
278. [278] Giorgetti, S., Raimondi, S., Pagano, K., Relini, A., Bucciantini, M., Corazza, A., Fogolari, F., Codutti, L., Salmona, M., Mangione, P., Colombo, L., De Luigi, A., Porcari, R., Gliozzi, A., Stefani, M., Esposito, G., Bellotti, V., Stoppini, M., Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils. J. Biol. Chem. 286 (2011), 2121–2131.
279. [279] Karamanos, T.K., Kalverda, A.P., Thompson, G.S., Radford, S.E., Visualization of transient protein-protein interactions that promote or inhibit amyloid assembly. Mol. Cell 55 (2014), 214–226.